Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Eurofins Scientific    ERF   FR0014000MR3

EUROFINS SCIENTIFIC

(ERF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eurofins Scientific : World's Most Comprehensive Hemp and Medicinal Cannabis Genotyping Assay Hits the Market

10/27/2020 | 12:05pm EST

Eurofins Genomics (Paris:ERF), Eurofins BioDiagnostics and Medicinal Genomics Corp (MGC), announced the formal launch of commercial SNP genotyping services for hemp and medicinal cannabis breeders. The newly launched CannSNP90 genotyping assay is based on industry-leading array platforms and will aid customers with their efforts to develop hemp and cannabis cultivars that exhibit specific chemical profiles and disease resistant characteristics.

This new assay is intended to provide the best genetic solution for clients, helping them revolutionize breeding, genetic purity, and support IP around hemp and cannabis lines. Eurofins Genomics and Medicinal Genomics are amongst the premier providers of genetic analysis solutions for detection of genetic traits.

The chip was developed using Kannapedia®, the world's largest cannabis genomic database available through Medicinal Genomics, leveraging over 75,000 unique genetic features. Along with tens of thousands of high-impact coding SNPs, there are markers for 39 cannabinoid genes, plant sex, chemotypes (I-IV), and disease resistance captured on the array. These traits are the most important in the market. The data from the chip can be further analyzed using Kannapedia to gather population frequencies, Bt:Bd allele coverage, heterozygosity, relatedness to other cultivars and other genetic knowledge in the database.

This product has the potential for not just breeding, authentication and genotyping applications but also for further research in the field, ultimately helping customers bring to market safe and also innovative products.

A one-hour webinar on applications and use of the chip is planned for November 2020. Companies interested in learning more can register at: https://www.eurofinsus.com/biodiagnostics/resources/webinars/cannsnp90

The CannSNP90 chip is now available for orders.

For US-based entities visit www.medicinalgenomics.com/cannsnp90

For global customers outside the US visit https://go.eurofinsgenomics.eu/cannabis-hemp-testing/ or email: DNACannabis@eurofins.com

About Eurofins

With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

About Medicinal Genomics Corporation

Medicinal Genomics Corporation is a pioneer in advancing the genomics of cannabis to build a stronger scientific foundation for cannabis-based products. The company's unmatched expertise in genetic science helps customers characterize and understand the quality and consistency of cannabis to ensure patients and consumers access to consistently safe, high quality cannabis. For more information, please visit www.medicinalgenomics.com.


© Business Wire 2020
All news about EUROFINS SCIENTIFIC
08:48aEUROFINS SCIENTIFIC : Bioanalytical Services launches Surrogate Virus Neutralizi..
PU
01/15Eurofins Launches New Test, Increased Capacity to Detect SARS-CoV-2 Variants
MT
01/15EUROFINS : the global leader in analytical testing, expands worldwide face mask ..
BU
01/15EUROFINS SCIENTIFIC : Launches New Tests and Massive Capacity for Detecting and ..
BU
01/11EUROFINS SCIENTIFIC : Anti-COVID-19 System Gets Emergency Response Validation PT..
MT
01/11EUROFINS SCIENTIFIC : GeneScan Technologies Announces AOAC PTM Accreditation for..
BU
2020EUROFINS SCIENTIFIC : Launches Full-Length COVID-19Viral Genome Sequencing Servi..
MT
2020EUROFINS SCIENTIFIC : Genomics Launches Cost-Effective SARS-CoV-2 full-length Vi..
BU
2020EUROFINS CEREP : Launches PCR COVID-19 Self-Test In Germany, Spain
MT
2020EUROFINS SCIENTIFIC : launches COVID-19 PCR tests with at-home self-sampling opt..
PU
More news
Financials
Sales 2020 5 265 M 6 355 M 6 355 M
Net income 2020 391 M 473 M 473 M
Net Debt 2020 2 866 M 3 459 M 3 459 M
P/E ratio 2020 34,7x
Yield 2020 0,67%
Capitalization 14 262 M 17 243 M 17 215 M
EV / Sales 2020 3,25x
EV / Sales 2021 3,01x
Nbr of Employees 48 000
Free-Float 66,7%
Chart EUROFINS SCIENTIFIC
Duration : Period :
Eurofins Scientific Technical Analysis Chart | ERF | FR0014000MR3 | MarketScreener
Technical analysis trends EUROFINS SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 73,55 €
Last Close Price 74,75 €
Spread / Highest target 13,8%
Spread / Average Target -1,60%
Spread / Lowest Target -48,9%
EPS Revisions
Managers and Directors
NameTitle
Gilles J. Martin Chairman & Chief Executive Officer
Laurent Lebras Director-Group Finance & Administration
Andreas König Chief Information Officer
Yves-Loïc Martin Non-Executive Director
Valérie Hanote Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
EUROFINS SCIENTIFIC8.92%17 243
SQUARE, INC.4.65%102 701
FISERV, INC.-4.97%72 541
GLOBAL PAYMENTS INC.-11.16%57 287
CINTAS CORPORATION-7.75%34 247
OFFCN EDUCATION TECHNOLOGY CO., LTD.-5.21%31 695